U.S. Patent and Traderanty Office, U.S. DePARTMENT OF COMMERCE

U.S. Patent and Traderanty Office, U.S. DePARTMENT OF COMMERCE

TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING | Docket Number (Optional) PTO/SB/25 (07-09)

REJECTION OVER A PENDING "REFERENCE" APPLICATION

068911-0075

In re Application of John G. Babish, et al

Application No.: 10/789,814

Filed: February 27, 2004

SYNERGISTIC ANTHNELAMMATORY PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE

except as provided below. The terminal part of the statutory term of any balant granted on the instant application which would extend beyond the expiration date of the full statutory term of any patent granted on pending reference Application Number. 10:532.388.

In 2012 12005

Application may be shortened by any terminal disclaimer filed prior to the grant of any patent granted on said reference application. The owner filed prior to the grant of any patent granted on the paticial is and any patent filed prior to the grant of any for and during such period that it and any patent granted on the instant application are commonly owned. This agreement runs with any patent granted on the instant application and is sometimes to the grant of the prior on the instant application and is sometimes. The owner METAPROTEOMICS, LLC 2 100 percent interest in the instant application hereby disclaims

binding upon the grantee, its successors or assigns

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any patent granted on said reference application, as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application. In the event that any such patent on the pending reference application, in the event that any such patent of any patent on the pending reference application. In the event that any such patent of competent jurisdiction, is statutorily disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal declaimer discrete patent in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer to six grant.

For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency etc.), the undersigned is empowered to act on behalf of the business/organization.

Check either box 1 or 2 below, if appropriate

belief are believed to be true; and further that these return or my very ancovering an every and made an adelinent made on information and the like so made are purishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful faise statements and statements and the like so statements may jeopardize the validity of the application or any patent issued thereon.	ful false statements and the like s tes Code and that such willful fals
2 The undersigned is an attorney or agent of record. Reg. No. <u>59,037</u>	
Liver Com	December 9, 2010
Signature	Date
Atabak Royaee Typed or printed name	
	(617) 535-4108 Telephone Number
[X] Terminal disclaimer fee under 37 CFR 1.20(d) is included.	
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.	n should not n PTO-2038.
*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).	

From Pt 10/SB/96 may be used for making this statement. See MPEP \$ 324.

This collection of information is required by 37 CFR 1 321. The information is croquired to obtain or return a benefit by the public which is to file (and by the USPTO includes a minute of the collection) are approximated by 37 CFR 1 321. The information is croquired to obtain 3 period by 37 CFR 1 321. The public which is the information of the public of the information officer. U.S. Fatent and of the public o